Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Remimazolam Besylate for Injection

Approval Number

国药准字H20227087

Company宜昌人福药业有限责任公司

Registration Date

June 29, 2022

Previous Approval Numbers

国药准字H20200006

Drug Information

Generic Name

注射用苯磺酸瑞马唑仑

Trade Name

锐马

Dosage Form

注射剂

Strength

50mg（按C₂₁H₁₉BrN₄O₂计）

Drug Type

化学药品

Registration Date

June 29, 2022

Company Information

Applicant Company

Company Name宜昌人福药业有限责任公司

Company Address

湖北省宜昌开发区大连路19号

Manufacturing Company

Company Name宜昌人福药业有限责任公司

Company Address

湖北省宜昌开发区大连路19号

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy

注射用苯磺酸瑞马唑仑 - NMPA 批准文号 | MedPath